Camrelizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Camrelizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
963
Registered trials
458
Result records
5
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Camrelizumab can convert its Monoclonal antibody profile and PD-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Camrelizumab (query alias: camrelizumab) |
|---|---|
| Modality / target | Monoclonal antibody; PD-1; PD-1 inhibitors, ADCC, T lymphocytes stimulants |
| Highest global status | Approved |
| Originator | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| Active developers | Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Luzsana Biotechnology, Inc. |
The MCP disease footprint includes Metastatic Cervical Carcinoma, Recurrent Cervical Cancer, Advanced Hepatocellular Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07653451 | Phase 2/3 | Not yet recruiting | 90 | Progression-Free Survival (PFS) |
| ChiCTR2600126661 | Phase 2 | Not yet recruiting | 40 | Objective Response Rate, ORR |
| ChiCTR2600127200 | Phase 2 | Not yet recruiting | 37 | Pathological complete remission rate |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Transarterial embolization plus hepatic arterial infusion chemotherapy combined with rivoceranib and camrelizumab for initially unresectable hepatocellular carcinoma with high tumor burden: A single-arm, prospective, multicenter study.
Phase 2; n=51; evaluation: Positive. Reported fields: ORR(RECIST1.1) = 64.7 %
Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial.
Phase 2; n=19; evaluation: Positive. Reported fields: MPR = 60.0 %
Fatty acid degradation (FAD)–guided comprehensive therapy for unresectable hepatocellular carcinoma: A prospective phase II study (FAD-HCC-01).
Phase 2; n=86; evaluation: Positive. Reported fields: AE = The most common treatment-related adverse events were Grade 2-3 hypertension (camrelizumab, 53.8%; TACE, 39.7%) and Grade 1-2 diarrhea (rivoceranib, 47.6%). ; AE = The most common treatment-related adverse events were Grade 2-3 hypertension (camrelizumab, 53.8%; TACE, 39.7%) and Grade 1-2 diarrhea (rivoceranib, 47.6%).
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Camrelizumab addresses Metastatic Cervical Carcinoma, Recurrent Cervical Cancer, Advanced Hepatocellular Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-05-14 | HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui | Approved | Financial terms not disclosed |
| 2023-12-07 | 中国江苏恒瑞医药股份有限公司与俄罗斯制药企业“Petrovax”就多种抗癌药物的购销及后续国产化问题达成协议 | Approved | Financial terms not disclosed |
| 2020-04-20 | 江苏恒瑞医药股份有限公司关于许可韩国 CrystalGenomics 公司在韩国开发和销售PD-1 单克隆抗体的公告 | Approved | US$1.5M upfront; US$85.8M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods of treating multiple myeloma with BCMA inhibitors in combination with PD1/PD-l1 inhibitors”. The milestone feed surfaced a patent-application signal described as “Application of combination of OH2 oncolytic virus and PD-1 inhibitor in preparation of antitumor drugs”. The milestone feed surfaced a patent-application signal described as “Treatment of tumors by means of Anti-tigit antibody in combination with Anti-PD-1 antibody”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
